89. Lymphangioleiomyomatosis Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 38 / Drugs : 38 - (DrugBank : 15) / Drug target genes : 18 - Drug target pathways : 118
Lymphangioleiomyomatosis and other diseases between which drug repositioning might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Drug repositionability
| ID | Diseases (Sorted by drug repositionability) |
|---|---|
| 89 | Lymphangioleiomyomatosis |
| 85 | Idiopathic interstitial pneumonia |
| 34 | Neurofibromatosis |
| 86 | Pulmonary arterial hypertension |
| 6 | Parkinson disease |
| 13 | Multiple sclerosis/Neuromyelitis optica |
| 51 | Scleroderma |
| 2 | Amyotrophic lateral sclerosis |
| 227 | Osler disease |
| 102 | Rubinstein-Taybi syndrome |
| 256 | Muscle glycogenosis |
| 331 | Idiopathic multicentric castleman disease |
| 222 | Primary nephrotic syndrome |
| 228 | Bronchiolitis obliterans |
| 233 | Wolfram syndrome |
| 5 | Progressive supranuclear palsy |
| 65 | Primary immunodeficiency |
| 3 | Spinal muscular atrophy |
| 87 | Pulmonary veno-occlusive disease |
| 28 | Systemic amyloidosis |
| 67 | Polycystic kidney disease |
| 127 | Frontotemporal lobar degeneration |
| 90 | Retinitis pigmentosa |
| 26 | HTLV-1-associated myelopathy |
| 46 | Malignant rheumatoid arthritis |
| 35 | Pemphigus |
| 276 | Achondroplasia |
| 88 | Chronic thromboembolic pulmonary hypertension |
| 158 | Tuberous sclerosis |
| 96 | Crohn disease |
| 58 | Hypertrophic cardiomyopathy |
| 215 | Tetralogy of Fallot |
| 8 | Huntington disease |
| 49 | Systemic lupus erythematosus |
| 162 | Pemphigoid |
| 137 | Focal cortical dysplasia |
| 192 | Cockayne syndrome |
| 277 | Lymphangiomatosis |
| 281 | Klippel-Trenaunay-Weber syndrome |
| 111 | Congenital myopathy |